ClinicalTrials.gg
RecruitingNCT02915198VA-IMPACTUpdated Dec 17, 2025

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

A Phase 4 interventional study of Metformin XR and Placebo in Prediabetic State, Atherosclerosis and Metformin, sponsored by VA Office of Research and Development. Recruiting at 40 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by VA Office of Research and Development · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
7,410
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing metformin in Prediabetic State — 2 open to participants now, 4 under way, none of them phase 3. Metformin · Prediabetic State.

Planned enrollment
Largest of 33
7,410 · median 46
Started
2023
with 2 others
Phase 4
14 of 33
2 open now
Registered
12th of 33
by date
Lead sponsor
2 of 33
VA Office of Research and Development

Among the 33 studies testing metformin in Prediabetic State, this one has the largest planned enrollment, is one of 3 that started in 2023, is one of 14 in phase 4, and was the 12th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

2 of the 33 studies testing metformin in Prediabetic State are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing metformin in Prediabetic State, or all of them as a file.
02

Study summary

This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.

Read the detailed description

CSP #2002 is a multicenter, prospective, randomized, double blind, secondary prevention trial to test the hypothesis that treatment with metformin, compared with placebo, reduces mortality and cardiovascular morbidity in Veterans with pre-diabetes and established atherosclerotic cardiovascular disease. Qualifying patients have pre-diabetes defined by HbA1c, fasting blood glucose, or oral glucose tolerance test criteria; clinically evident coronary, cerebrovascular, or peripheral arterial atherosclerotic cardiovascular disease; and estimated glomerular filtration rate of at least 45 mL/min/1.73 m2; and do not fulfill any exclusion criteria. Patients who are eligible and agree to participate are randomly assigned to treatment with metformin XR (titrated to a maximum dose of 2000 mg daily based on safety and tolerability) or matching placebo. All patients receive counseling on therapeutic lifestyle recommendations.

CSP #2002 had a Pilot Phase trial from 2/2019 to 1/2021 and was approved for the full-scale trial, with Full-scale study launch in 04/2023.

03

Conditions studied

  • Prediabetic State
  • Atherosclerosis
  • Metformin

Keywords

  • Metformin
  • Atherosclerosis
  • Prediabetic State
  • Hemoglobin A, Glycosylated
  • Coronary Artery Disease
  • Peripheral Arterial Disease
  • Cerebrovascular Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pre-diabetes: This condition is fulfilled by of at least 5.7%, but less than 6.5%; or two measurements of fasting plasma glucose (on separate days) of 100-125 mg/dL; or a 2-hour plasma glucose level of 140-199 mg/dL following a 75 g glucose load oral glucose tolerance test.
  2. Established atherosclerotic cardiovascular disease: Qualifying participants must have evidence of atherosclerotic disease in at least one of the following vascular beds: coronary, cerebrovascular, or peripheral arterial circulation.

Coronary artery disease is fulfilled by at least one of (1), (2), or (3):

  1. History of myocardial infarction at least one month prior to randomization.
  2. History of percutaneous coronary intervention or coronary artery bypass surgery at least one month prior to randomization.
  3. Angiographic evidence of coronary stenosis of at least 50% in at least two major epicardial coronary arteries.

Cerebrovascular disease is fulfilled by at least one of criteria (1) through (4):

  1. Documented prior ischemic stroke (at least one month prior to randomization),
  2. Carotid artery stenosis 50% and history of or transient ischemic visual symptoms attributable to the identified lesion(s),
  3. Asymptomatic carotid stenosis of at least 70% luminal diameter,
  4. History of carotid revascularization (surgical or catheter-based).

Peripheral arterial disease: Fulfilled by at least one of the following:

  1. History of aorto-iliac or peripheral artery intervention (surgical or catheter based) for limb ischemia, or amputation for limb ischemia,
  2. Symptoms of intermittent claudication with ankle:brachial index less than or equal to 0.85.

3. Renal function: Estimated at least 45 mL/min/1.73 m2.

4. has been fully executed, and participant agrees to study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with metformin or other anti-diabetic medication within 12 months of randomization. Note: In the absence of a diagnosis of diabetes, inpatient treatment with insulin or treatment with an SGLT2 inhibitor (e.g., for heart failure) or a GLP-1 receptor agonist (e.g., for obesity) is not exclusionary.
  2. Treatment with systemic within 3 months of randomization
  3. Fasting plasma glucose greater than 130 mg/dL measured between screening and randomization visits, or any plasma glucose 180 mg/dL or 7.0% measured within 12 months of randomization.
  4. Total CO2 below the local laboratory lower limit of normal on most recent blood chemistry panel
  5. Current treatment with cimetidine, vandetanib, or a systemic treatment with a carbonic anhydrase inhibitor.
  6. Cirrhosis, active hepatitis, or jaundice at time of randomization, or total > 2 times
  7. Binge or heavy alcohol consumption within 6 months of randomization
  8. Severe anemia ( \< 10 g/dL)
  9. Prior history of intolerance to metformin
  10. Myocardial infarction, coronary revascularization procedure, or stroke within 1 month of randomization
  11. Uncontrolled hypertension at screening assessment (systolic blood pressure 180 mm Hg or diastolic blood pressure 110 mm Hg
  12. Acute or decompensated congestive heart failure
  13. Expected survival less than study duration
  14. Participants considered to be unable, unwilling, or unreliable to meet protocol requirements
  15. Impaired decision-making capacity, defined by any history of dementia or cognitive impairment
  16. Concurrent participation in another research study involving a randomized comparison of drug or device treatments, unless specifically excepted.
  17. Pregnant, intent to become pregnant during the trial, or lactating
  18. Women of who are not using a highly effective method of
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7,410 participants (estimated)

Study arms

  • Experimental
    Metformin

    Participants receive initial treatment with metformin XR 500 mg 1 tablet daily, with stepwise titration to a maximum dose of 2000 mg (4 tablets) daily.

    Drug: Metformin XR

  • Placebo comparator
    Placebo

    Participants receive initial treatment with 1 tablet daily of placebo (for metformin XR), with stepwise titration to a maximum of 4 tablets daily.

    Drug: Placebo

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.

  • DrugPlacebo

    For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo. For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo

06

What researchers measure

Primary outcomes

  1. Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization

    The primary outcome measure is the time to first occurrence of death, non-fatal myocardial infarction or stroke, hospitalization for unstable angina with objective evidence of acute myocardial ischemia, or coronary revascularization driven by acute or progressive symptoms.

    Time frame: through study completion, an average of 4.5 years

Secondary outcomes

  1. Time in days to Cardiovascular Outcomes

    * Time to first occurrence of death, myocardial infarction, or stroke * Time to first occurrence of a primary endpoint event, peripheral arterial disease event, or hospitalization for congestive heart failure * Cumulative incidence of all components of the primary endpoint, including recurrent or multiple events in the same participant * Cumulative incidence and time to first occurrence of each component of the primary outcome measure, peripheral arterial disease events, and hospitalization for congestive heart failure

    Time frame: through study completion, an average of 4.5 years

  2. Time in days to Oncologic Outcome

    Time to new or recurrent diagnosis of a malignancy or death from a malignancy

    Time frame: through study completion, an average of 4.5 years

  3. Time in days to Diabetes Outcome

    Time to new diagnosis of type 2 diabetes

    Time frame: through study completion, an average of 4.5 years

07

Study locations

37 of 40 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Sep 2029, 77 months after the start.

Of 30 phase 4 interventional studies under Prediabetic State, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 47. This study's planned 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2016
First posted
Sep 26, 2016
StartActual
Apr 3, 2023
Primary completionEst.
Sep 28, 2029
CompletionEst.
Sep 28, 2029
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02915198
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Apr 3, 2023
Primary completion
Sep 28, 2029 (estimated)
Completion
Sep 28, 2029 (estimated)
Last update
Dec 17, 2025

Study contacts

Gregory G Schwartz, PhD MD
Contact
Gregory.Schwartz@va.gov
(720) 723-6070
Kevin Gropp
Contact
kevin.gropp@va.gov
(720) 857-5659
Gregory G. Schwartz, PhD MD
study chair · Rocky Mountain Regional VA Medical Center, Aurora, CO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion